First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

Published:2023-11-16 Issue:20 Volume:389 Page:1839-1850
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Zhou Caicun¹,Solomon Benjamin¹,Loong Herbert H.¹^ORCID,Park Keunchil¹,Pérol Maurice¹,Arriola Edurne¹,Novello Silvia¹,Han Baohui¹,Zhou Jianying¹,Ardizzoni Andrea¹,Mak M. Perez¹,Santini Fernando C.¹,Elamin Yasir Y.¹,Drilon Alexander¹,Wolf Jürgen¹,Payakachat Nalin¹,Uh Minji K.¹,Rajakumar Deborah¹,Han Hongmei¹,Puri Tarun¹,Soldatenkova Victoria¹,Lin A. Bence¹,Lin Boris K.¹,Goto Koichi¹

Affiliation:

1. From Shanghai Pulmonary Hospital, Tongji University School of Medicine (C.Z.), and the Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University (B.H.), Shanghai, the Chinese University of Hong Kong, Hong Kong (H.H.L.), and the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou (J.Z.) — all in China; Peter MacCallum Cancer Institute, Melbourne, VIC, Australia (B.S.); Samsung Medical Center, Sungkyunkwan...

Funder

National Cancer Institute

National Institutes of Health

Loxo Oncology, a wholly owned subsidiary of Eli Lilly

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2309457

Reference22 articles.

1. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer